Literature DB >> 25600719

The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies.

Rebecca C Burch1, Stephen Loder, Elizabeth Loder, Todd A Smitherman.   

Abstract

BACKGROUND AND OBJECTIVES: The US National Center for Health Statistics, which is part of the Centers for Disease Control, conducts ongoing public health surveillance activities. The US Armed Forces also maintains a comprehensive database of medical information. We aimed to identify the most current prevalence estimates of migraine and severe headache in the United States adult civilian and active duty service populations from these national government surveys, to assess stability of prevalence estimates over time, and to identify additional information pertinent to the burden and treatment of migraine and other severe headache conditions.
METHODS: We searched for the most current publicly available summary statistics from the National Ambulatory Medical Care Survey, the National Hospital Ambulatory Medical Care Survey, and the National Health Interview Survey (NHIS). Summary data from the Defense Medical Surveillance System were also obtained, and PubMed was also searched for publications reporting summary statistics based on these studies. Data were abstracted, double-checked for accuracy, and summarized over time periods and as a function of demographic variables.
RESULTS: 14.2% of US adults 18 or older reported having migraine or severe headache in the previous 3 months in the 2012 NHIS. The overall age-adjusted 3-month prevalence of migraine in females was 19.1% and in males 9.0%, but varied substantially depending on age. The prevalence of migraine was highest in females 18-44, where the 3-month prevalence of migraine or severe headache was 23.5%. The 3-month prevalence of migraine or severe headache has remained relatively stable over the period of2005-2012, with an average prevalence of 20.2% in females, 9.4% in males, and 14.9% overall [corrected]. During this time, the average female to male sex ratio for migraine or severe headache was 2.17. The unadjusted 1-year prevalence of migraine in active duty US military service members varied from 1% to 1.9% between 1998 and 2010, ranging from 0.7% to 1.2% in males and 3.5% to 6% in females. The 1-year prevalence of "other headache" in this military population ranged from a low of 1.9% in 2003 to a high of 3% in 2010. Headache or pain in the head was the fourth leading cause of visits to the emergency department (ED) in 2009-2010, accounting for 3.1% of all ED visits. Across all ambulatory care settings, migraine accounted for 0.5% of all visits and other headache presentations for 0.4% of all ambulatory care visits. 52.8% of all visits for migraine occurred in primary care settings, 23.2% in specialty outpatient settings, and 16.7% in EDs. In 2010, opioids were administered at 35% of ED visits for headache, while triptans were administered in only 1.5% of visits.
CONCLUSIONS: This report summarizes the most recent government statistics on the prevalence and burden of migraine and severe headache in the US civilian and active duty military populations. The prevalence of migraine headaches is high, affecting roughly 1 out of every 7 Americans annually, and has remained relatively stable over the last 8 years. Migraine and headache are leading causes of outpatient and ED visits and remain an important public health problem, particularly among women during their reproductive years.
© 2015 American Headache Society.

Entities:  

Keywords:  epidemiology; headache; migraine; military; prevalence

Mesh:

Year:  2015        PMID: 25600719     DOI: 10.1111/head.12482

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  139 in total

1.  Development of a measure of self-efficacy for acute headache medication adherence.

Authors:  Elizabeth K Seng; Robert A Nicholson; Kenneth A Holroyd
Journal:  J Behav Med       Date:  2015-09-24

2.  The diagnosis and treatment of chronic migraine: the case for daily scheduled opioid treatment in chronic headache.

Authors:  Iraj Derakhshan
Journal:  Ther Adv Chronic Dis       Date:  2015-11       Impact factor: 5.091

3.  Chronic Orofacial Pain: Burning Mouth Syndrome and Other Neuropathic Disorders.

Authors:  Raymond C Tait; McKenzie Ferguson; Christopher M Herndon
Journal:  J Pain Manag Med       Date:  2017-01-30

4.  Influences on headache trigger beliefs and perceptions.

Authors:  Dana P Turner; Timothy T Houle
Journal:  Cephalalgia       Date:  2017-10-30       Impact factor: 6.292

5.  The sensorimotor network dysfunction in migraineurs without aura: a resting-state fMRI study.

Authors:  Jilei Zhang; Jingjing Su; Mengxing Wang; Ying Zhao; Qi-Ting Zhang; Qian Yao; Haifeng Lu; Hui Zhang; Ge-Fei Li; Yi-Lan Wu; Yi-Sheng Liu; Feng-Di Liu; Mei-Ting Zhuang; Yan-Hui Shi; Tian-Yu Hou; Rong Zhao; Yuan Qiao; Jianqi Li; Jian-Ren Liu; Xiaoxia Du
Journal:  J Neurol       Date:  2017-02-02       Impact factor: 4.849

6.  Focus group findings on the migraine patient experience during research studies and ideas for future investigations.

Authors:  Mia T Minen; Kaitlyn Morio; Kathryn Berlin Schaubhut; Scott W Powers; Richard B Lipton; Elizabeth Seng
Journal:  Cephalalgia       Date:  2019-12-23       Impact factor: 6.292

Review 7.  [Peppermint oil in the acute treatment of tension-type headache].

Authors:  H Göbel; A Heinze; K Heinze-Kuhn; A Göbel; C Göbel
Journal:  Schmerz       Date:  2016-06       Impact factor: 1.107

Review 8.  A new era in headache treatment.

Authors:  Michail Vikelis; Konstantinos C Spingos; Alan M Rapoport
Journal:  Neurol Sci       Date:  2018-06       Impact factor: 3.307

9.  Rate and Prognosis of Brain Ischemia in Patients With Lower-Risk Transient or Persistent Minor Neurologic Events.

Authors:  Shelagh B Coutts; Francois Moreau; Negar Asdaghi; Jean-Martin Boulanger; Marie-Christine Camden; Bruce C V Campbell; Andrew M Demchuk; Thalia S Field; Mayank Goyal; Martin Krause; Jennifer Mandzia; Bijoy K Menon; Robert Mikulik; Andrew M Penn; Richard H Swartz; Michael D Hill
Journal:  JAMA Neurol       Date:  2019-12-01       Impact factor: 18.302

Review 10.  Novel Interventional Nonopioid Therapies in Headache Management.

Authors:  Omar Viswanath; Roxanna Rasekhi; Rekhaben Suthar; Mark R Jones; Jacquelin Peck; Alan D Kaye
Journal:  Curr Pain Headache Rep       Date:  2018-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.